Archive for the 'Pemetrexed (Alimta)' Category
March 16th, 2007. Emerging drugs for mesothelioma
At present, the regimen of cisplatin/pemetrexed is the medical treatment of choice. This review summarizes standard chemotherapy options and focusses on the molecular basis of the newest biologically targeted therapies to be implemented in the near future, in the management of MPM.
February 23rd, 2007. Investigation of allergic reactions to platinum salts
Conclusion: Hypersensitivity to platinum salts usually occurs after several courses of treatment. Skin tests and flow cytometry are a simple, concordant, and reliable way of confirming the diagnosis.
Posted in Carboplatin, Case Study, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
February 22nd, 2007. Preliminary Data Suggestive Of A Novel Translational Approach To Mesothelioma Therapy: Imatinib Mesylate With Gemcitabine Or Pemetrexed
Among chemotherapeutics tested in combination, Imatinib synergizes with Gemcitabine and Pemetrexed. We provide a rationale for a novel translational approach to mesothelioma therapy, relying on enhancement of tumor chemosensitivity, via inhibition of Akt.
February 20th, 2007. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
This is due to concurrent contraction of competing cellular physiologic folates and utilization of a novel second transport carrier for which pemetrexed has high affinity, recently identified as the proton-coupled folate transporter (PCFT). Laboratory studies are reviewed that raise the possibility of new approaches to the use of folic acid supplementation in clinical regimens with pemetrexed.
February 16th, 2007. Expanded access program in the United States and Alimta program for malignant mesothelioma patients
Eli Lilly conducted Alimta Expanded Access Programs for 1200 malignant mesothelioma patients with free of charge and obtained clinical efficacy and severe adverse events. The system development for Expanded Access Program should be discussed for future Japanese participation to this program.
January 27th, 2007. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma
The results indicate that pemetrexed used in combination with cisplatin significantly increases the length of survival, when compared with cisplatin alone. Further research is needed into the optimum treatment regimen for pleural mesothelioma.
January 27th, 2007. A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Conclusions: The pemetrexed/irinotecan regimen is well tolerated in patients with advanced solid malignancies at clinically relevant single-agent doses. The recommended dose level of pemetrexed/irinotecan for subsequent disease-directed evaluations involving lightly pretreated patients is 500/350 mg/m2 every 3 weeks with vitamin supplementation.
January 6th, 2007. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial
4%. Our data show that TSP is a relatively effective second-line treatment in patients with progressive disease after systemic chemotherapy, with a low rate of major complications and treatment-related toxicity.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, melphalan, mitomycin-C, Pemetrexed (Alimta), Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 21st, 2006. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report
Conclusion: Single-agent pemetrexed is a treatment option for malignant peritoneal mesothelioma in selected elderly patients or in patients with unpaired performance status.
November 10th, 2006. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access program
Conclusions: In this large cohort, 67.7% of patients treated with first-line chemotherapy experienced a response or stable disease. Survival time and toxicity from this EAP were promising for this difficult-to-treat disease.
November 1st, 2006. Efficacy of a combination of pemetrexed and multiple redo-surgery in an 11-year-old girl with a recurrent multifocal abdominal mesothelioma
Fourteen months after the surgery, the girl remained in partial remission with stable disease. So far, pemetrexed associated with cisplatin revealed a good tolerance and promising results regarding its antitumoral efficacy in a progressive metastatic abdominal mesothelioma in childhood.
October 28th, 2006. Can pemetrexed help in malignant mesothelioma?
Currently, this is the only chemotherapy regimen licensed for patients with malignant pleural mesothelioma in the UK. Here we review the care of patients with malignant pleural mesothelioma, focusing on what, if anything, pemetrexed might offer such individuals.
October 17th, 2006. The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity
There is a modest salutary effect when the pemetrexed target is GARFT alone. [Mol Cancer Ther 2006;5(10):2549–55].
September 30th, 2006. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose
Conclusion: The use of MR evaluated by FDG-PET in the assessment of treatment efficacy in MPM appears promising. Our observations need to be validated in a larger prospective series.
Posted in Chemotherapy, CT or CAT scan, Determining Efficacy, Diagnosis & Differentiation, Full Archive, Pemetrexed (Alimta), PET Scan, Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
September 27th, 2006. Pemetrexed-induced edema of the eyelid
We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known.
September 15th, 2006. Malignant pleural mesothelioma (MPM) – 5 years of experience
Discussion: S rarely is the treatment of choice, once most of the patients have local advanced disease, old age and comorbilities. The epithelium mesothelioma was the prevalent histological type and because of the few number of patients with other types, it was not possible to establish significant relationships between the histological type and the overall survival. The survival tends to increase, 3 patients were treated with second line Ct and 1 with third line Ct.
Posted in Carboplatin, Causation, Chemotherapy, Determining Efficacy, Epithelioid, Full Archive, Gemcitabine (Gemzar), General, Occupational Asbestos Exposure, Pemetrexed (Alimta), Radiation, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
September 15th, 2006. Malignant mesothelioma: A ten years experience
Discussion: As demonstrated by the small series in ten years, malignant mesothelioma is a rare tumour. Relationship with asbestos exposure was proven in 67% of cases. Chemotherapy associated with talc pleurodesis increased survival and palliated symptoms.
Posted in Carboplatin, Causation, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Diagnosis & Differentiation, Full Archive, Gemcitabine (Gemzar), General, Occupational Asbestos Exposure, Pemetrexed (Alimta), Pleural Biopsy, Pleural Effusion, Pneumonectomy, Radiation, Surgery, Survival, Symptoms & Symptom Management, Treatment, Type of Assessment: | No Comments »
August 11th, 2006. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro
Our results suggest that the simultaneous clinical administration of pemetrexed and cisplatin may be suboptimal. The optimal schedule of pemetrexed in combination with cisplatin at the cellular level is the sequential administration of pemetrexed followed by cisplatin and this schedule is worthy of clinical investigations.
July 20th, 2006. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates
Conclusion: The CSF penetration of pemetrexed was less than 2% (range 0.33–1.58%), suggesting that it should be used in conjunction with other CNS preventive strategies when used in the treatment of malignancies with a predilection for CNS or leptomeningeal metastases.
|
|  |
